Jump Financial LLC Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Jump Financial LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 92.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,144 shares of the medical device company's stock after selling 139,343 shares during the quarter. Jump Financial LLC's holdings in DexCom were worth $944,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of DXCM. Aware Super Pty Ltd as trustee of Aware Super bought a new stake in DexCom in the 4th quarter worth $7,646,000. Canada Post Corp Registered Pension Plan bought a new position in DexCom during the 4th quarter valued at approximately $478,000. Mariner LLC lifted its holdings in DexCom by 1.5% in the 4th quarter. Mariner LLC now owns 29,729 shares of the medical device company's stock worth $2,312,000 after buying an additional 442 shares during the period. Sagespring Wealth Partners LLC purchased a new position in shares of DexCom during the fourth quarter valued at approximately $418,000. Finally, Townsquare Capital LLC lifted its stake in DexCom by 288.7% in the fourth quarter. Townsquare Capital LLC now owns 37,191 shares of the medical device company's stock worth $2,892,000 after acquiring an additional 27,623 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 over the last ninety days. Corporate insiders own 0.32% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Citigroup upped their price target on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and upped their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $99.00.

DexCom Stock Performance

DexCom stock traded up $0.88 during midday trading on Friday, hitting $71.66. The stock had a trading volume of 2,857,981 shares, compared to its average volume of 4,237,081. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $138.81. The company has a market capitalization of $28.10 billion, a PE ratio of 50.11, a P/E/G ratio of 2.30 and a beta of 1.50. The firm's fifty day moving average is $73.09 and its two-hundred day moving average is $76.63. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.